Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anebulo Pharmaceuticals ( (ANEB) ) has shared an announcement.
On January 29, 2026, Anebulo Pharmaceuticals reported the final results of its voluntary self-tender offer, which expired on January 26, 2026, to repurchase up to 300,000 shares of common stock at $3.50 per share. The offer was heavily oversubscribed, with 4,907,881 shares validly tendered and not withdrawn; Anebulo ultimately bought the full 300,000-share maximum, including 134,306 odd-lot shares accepted in full, at an aggregate cost of about $1.05 million, representing approximately 0.73% of shares outstanding as of January 26, 2026. The shares, other than odd lots, were accepted on a pro rata basis using a final proration factor of 3.47392%, and payment in cash without interest will be made promptly to participating shareholders. Management said the transaction met its goal of offering smaller shareholders a chance to exit at a significant premium to market while modestly shrinking the shareholder base, a move that could streamline the company’s investor roster without materially affecting its capital structure.
The most recent analyst rating on (ANEB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.
Spark’s Take on ANEB Stock
According to Spark, TipRanks’ AI Analyst, ANEB is a Neutral.
The score is driven primarily by weak financial performance (pre-revenue, ongoing losses and cash burn) and bearish technicals (below major moving averages with negative MACD). Valuation is hard to anchor due to a negative P/E, and recent corporate actions add uncertainty around a going-private path despite a modest buyback effect.
To see Spark’s full report on ANEB stock, click here.
More about Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., based in Austin, Texas, is a clinical-stage pharmaceutical company focused on developing novel treatments for cannabis-induced toxicity. Its lead candidate, selonabant, a competitive CB1 receptor antagonist, has completed a Phase 2 trial in adults with acute cannabinoid intoxication, and the company is currently prioritizing an intravenous formulation aimed at pediatric patients with acute cannabis-induced toxicity, with a Phase 1 single-ascending-dose study of IV selonabant initiated in September 2025.
Average Trading Volume: 63,737
Technical Sentiment Signal: Sell
Current Market Cap: $37.39M
Learn more about ANEB stock on TipRanks’ Stock Analysis page.